S&P Futures
6,004.00 +0.25 (+0.00%) Dow Futures
43,898.00 -12.00 (-0.03%) Nasdaq Futures
21,227.00 +2.25 (+0.01%) Russell 2000 Futures
2,396.00 +0.30 (+0.01%) Crude Oil
71.70 -0.66 (-0.91%) Gold
2,694.20 -11.60 (-0.43%)
Gain Therapeutics, Inc. (GANX)
After hours:
- GlobeNewswire
Gain Therapeutics Presents Data at 36ᵗʰ EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics Demonstrating Identification of Allosteric Inhibitors Targeting DDR2
GT-03842, Identified by the Company’s Magellan Drug Discovery Platform, Effectively Hinders Phosphorylation and Activation of DDR2 GT-03842 May Offer Potential Favourable Therapeutic Attributes for Oncology Compared to Traditional Kinase Inhibitors BETHESDA, Md., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therap
- GlobeNewswire
Gain Therapeutics Announces Poster Presentation at 36th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
BETHESDA, Md., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced that a poster detailing the use of the Company’s Magellan platform to discover novel allosteric discoidin domain receptor 2 (DDR2) inhibitors will be presented at the 36th EORTC-NCI-AACR (ENA) Symposium on molecular targets and
